Publications
Learn about the research supporting our preclinical and clinical development programs.
Publications
February 15, 2019 Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors
AACR Journals
June 6, 2018 Application of biomimetic HPLC to estimate lipophilicity, protein and phospholipid binding of potential peptide therapeutics
ADMET
March 8, 2018 Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema
Journal of Medicinal Chemistry
July 1, 2012 Bicyclic Peptides with Optimized Ring Size Inhibit Human Plasma Kallikrein and its Orthologues While Sparing Paralogous Proteases
ChemMedChem
May 31, 2009 Phage-encoded combinatorial chemical libraries based on bicyclic peptides
Nature Chem Bio
Presentations
May 2, 2019 Bicycles® – An entirely new class of therapeutics
30th Symposium on Medicinal Chemistry
April 25, 2019 Activation of CD137 using multivalent and tumour targeted bicyclic peptides
6th Annual Peptides Congress
April 3, 2019 Bicycles® – An entirely new class of therapeutics
ELRIG Research & Innovation
April 2, 2019 Activation of 4-1BB using multivalent and tumour targeted bicyclic peptides
AACR
April 2, 2019 BT5528, an EphA2-targeting Bicycle Toxin Conjugate (BTC): Profound efficacy without bleeding and coagulation abnormalities in animal models
AACR
April 2, 2019 BT8009: A bicyclic peptide toxin conjugate targeting Nectin-4 (PVRL4) displays efficacy in preclinical tumor models
AARC
March 6, 2019 BT5528: A Bicycle Toxin Conjugate Targeting EphA2 for the Treatment of Solid Tumours
9th Annual World ADC Conference
November 13, 2018 Preliminary pharmacokinetic assessment of BT1718: Aphase I/IIatrial of BT1718 (a first in class Bicycle Toxin Conjugate) in patients with advanced solid tumours
EORTC
November 13, 2018 BT5528, an EphA2-targeting Bicycle Toxin Conjugate (BTC): profound efficacy without bleeding and coagulation abnormalities in animal models
EORTC
November 12, 2018 Novel Multimers of Bicyclic Peptides Cluster and Activate CD137 (4-1BB): A Costimulatory T -Cell Checkpoint Receptor
PEGS
November 6, 2018 Activation of the T cell costimulatory protein CD137 using multivalent bicyclic peptides
SITC
October 9, 2018 Novel Bicyclic Peptide Multimers Activate T Cell Costimulatory Protein CD137
ELRIG Drug Discovery
October 9, 2018 Small Synthetic, Multivalent Bicyclic Peptides That Activate T Cell Costimulatory Protein CD137
ELRIG Drug Discovery
October 1, 2018 A Cancer Research UK phase I/IIa trial of BT1718 (a first in class Bicycle Toxin Conjugate) given intravenously in patients with advanced solid tumours
NCRI
August 31, 2018 Small Synthetic, Multivalent Bicyclic Peptides That Activate T Cell Costimulatory Protein CD137
35th European Peptide Symposium
July 18, 2018 Novel Bicyclic Peptide Multimers Activate T Cell Costimulatory Protein CD137
Promega Biologics
April 14, 2018 Bicycle Toxin Conjugates (BTCs) targeting EphA2 for the treatment of solid tumours: Discovery and selection of BT5528
AACR
April 14, 2018 BT5528, a Bicycle Toxin Conjugate (BTC) targeting EphA2 has potent anti-tumour activity without bleeding or coagulation abnormalities in animal models
AACR
April 14, 2018 Small Synthetic, Multivalent Bicyclic Peptides That Activate T Cell Costimulatory Protein CD137
AACR
April 30, 2017 Bicyclic Peptides for Positron Emission Tomography (PET) Imaging of MT1-MMP Expressing tumours
PEGS
April 30, 2017 BT1718, a novel Bicycle Drug Conjugate® shows potent anti-tumor activity in diverse cell-derived and patient-derived tumor xenograft models
PEGS
April 30, 2017 Identification of high affinity, highly selective bicyclic peptides (Bicycles®) to transmembrane proteins using phage display screening on whole cells
PEGS
April 1, 2017 Bicyclic Peptides for Positron Emission Tomography (PET) Imaging of MT1-MMP Expressing Tumors
AACR
April 1, 2017 Development of BT1718, a novel Bicycle Drug Conjugate for the treatment of lung cancer
AACR
